-transparent.png){kind=logo}
In earlier safety studies, naproxen, 600 mg three times daily, was administered to healthy subject without significant adverse effects. Another study demonstrated that single doses of 500 to 900 mg resulted in accelerated renal clearance and a nonlinear naproxen plasma level response after the higher doses. Our report describes the pharmacokinetics of naproxen when administered in single doses of 1, 2, 3, or 4 gm (up to eight times the clinically effective dose in rheumatoid arthritis) to healthy subjects. An increase in urinary excretion rate and continuation of the previously documented nonlinear plasma level response were observed. There were no signs that capacity to conjugate or to excrete the drug was exceeded. There were no adverse effects.
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
January 1995,
Journal of toxicology. Clinical toxicology,
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
January 1986,
Cephalalgia : an international journal of headache,
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
April 1997,
Clinical pharmacokinetics,
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
August 1984,
British journal of clinical pharmacology,
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
September 1981,
American journal of veterinary research,
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
January 1986,
European journal of clinical pharmacology,
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
January 1982,
Developmental pharmacology and therapeutics,
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
May 1996,
Biopharmaceutics & drug disposition,
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
July 1981,
International journal of clinical pharmacology, therapy, and toxicology,
R Runkel, and
M D Chaplin, and
H Sevelius, and
E Ortega, and
E Segre
January 1994,
Clinical therapeutics,
